Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.

Blood·2026
Same author

Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited.

Cancer immunology research·2025
Same author

Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA).

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2025
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Neurological manifestations of MGUS.

Hematology. American Society of Hematology. Education Program·2024
Same author

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.

JAMA oncology·2024

Related Experiment Video

Updated: Jun 8, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Multiple myeloma.

J Bladé1, M Teresa Cibeira, C Fernández de Larrea

  • 1Hematology Department, Hematology and Oncology Institute, IDIBAPS, Hospital Clínic, Barcelona, Spain. jblade@clinic.ub.es

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|October 15, 2010
PubMed
Summary

Multiple myeloma (MM) is a blood cancer preceded by monoclonal gammopathy of undetermined significance (MGUS). Treatment strategies vary based on patient eligibility for autologous stem cell transplantation (ASCT) and relapse status.

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Jun 8, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Area of Science:

  • Hematology
  • Oncology

Background:

  • Multiple myeloma (MM) accounts for 1% of all malignant diseases and 15% of hematological malignancies.
  • Monoclonal gammopathy of undetermined significance (MGUS) precedes MM in nearly all cases, but its causes and progression mechanisms remain unknown.

Purpose of the Study:

  • To outline current diagnostic criteria for MM.
  • To review key prognostic factors in MM.
  • To detail recommended treatment approaches for different patient groups.

Main Methods:

  • Diagnosis relies on M-protein detection, bone marrow plasma cell assessment, and organ impairment.
  • Prognostic factors include cytogenetic status and serum β2-microglobulin levels.
  • Treatment strategies are stratified by age, ASCT eligibility, and relapse status.

Main Results:

  • Younger patients benefit from triple-agent induction, ASCT, and novel agent consolidation with minimal residual disease monitoring.
  • ASCT-ineligible patients may receive melphalan/prednisone/thalidomide (MPT), melphalan/prednisone/bortezomib (MPV), or lenalidomide/dexamethasone.
  • Salvage therapy for relapsed MM depends on initial treatment, response, relapse type, prior toxicities, and patient status.

Conclusions:

  • Treatment decisions for MM require careful consideration of individual patient factors and disease characteristics.
  • Sequential therapy and supportive measures like bisphosphonates and erythropoietin are crucial.
  • Allogeneic transplantation remains an experimental but promising option.